Cargando…

Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor

The mechanism of muscle protein catabolism induced by proteolysis-inducing factor, produced by cachexia-inducing murine and human tumours has been studied in vitro using C(2)C(12) myoblasts and myotubes. In both myoblasts and myotubes protein degradation was enhanced by proteolysis-inducing factor a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes-Marcondes, M C C, Smith, H J, Cooper, J C, Tisdale, M J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746596/
https://www.ncbi.nlm.nih.gov/pubmed/12085214
http://dx.doi.org/10.1038/sj.bjc.6600236
_version_ 1782172054356754432
author Gomes-Marcondes, M C C
Smith, H J
Cooper, J C
Tisdale, M J
author_facet Gomes-Marcondes, M C C
Smith, H J
Cooper, J C
Tisdale, M J
author_sort Gomes-Marcondes, M C C
collection PubMed
description The mechanism of muscle protein catabolism induced by proteolysis-inducing factor, produced by cachexia-inducing murine and human tumours has been studied in vitro using C(2)C(12) myoblasts and myotubes. In both myoblasts and myotubes protein degradation was enhanced by proteolysis-inducing factor after 24 h incubation. In myoblasts this followed a bell-shaped dose-response curve with maximal effects at a proteolysis-inducing factor concentration between 2 and 4 nM, while in myotubes increased protein degradation was seen at all concentrations of proteolysis-inducing factor up to 10 nM, again with a maximum of 4 nM proteolysis-inducing factor. Protein degradation induced by proteolysis-inducing factor was completely attenuated in the presence of cycloheximide (1 μM), suggesting a requirement for new protein synthesis. In both myoblasts and myotubes protein degradation was accompanied by an increased expression of the α-type subunits of the 20S proteasome as well as functional activity of the proteasome, as determined by the ‘chymotrypsin-like’ enzyme activity. There was also an increased expression of the 19S regulatory complex as well as the ubiquitin-conjugating enzyme (E2(14k)), and in myotubes a decrease in myosin expression was seen with increasing concentrations of proteolysis-inducing factor. These results show that proteolysis-inducing factor co-ordinately upregulates both ubiquitin conjugation and proteasome activity in both myoblasts and myotubes and may play an important role in the muscle wasting seen in cancer cachexia. British Journal of Cancer (2002) 86, 1628–1633. DOI: 10.1038/sj/bjc/6600236 www.bjcancer.com © 2002 Cancer Research UK
format Text
id pubmed-2746596
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27465962009-09-18 Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor Gomes-Marcondes, M C C Smith, H J Cooper, J C Tisdale, M J Br J Cancer Experimental Therapeutics The mechanism of muscle protein catabolism induced by proteolysis-inducing factor, produced by cachexia-inducing murine and human tumours has been studied in vitro using C(2)C(12) myoblasts and myotubes. In both myoblasts and myotubes protein degradation was enhanced by proteolysis-inducing factor after 24 h incubation. In myoblasts this followed a bell-shaped dose-response curve with maximal effects at a proteolysis-inducing factor concentration between 2 and 4 nM, while in myotubes increased protein degradation was seen at all concentrations of proteolysis-inducing factor up to 10 nM, again with a maximum of 4 nM proteolysis-inducing factor. Protein degradation induced by proteolysis-inducing factor was completely attenuated in the presence of cycloheximide (1 μM), suggesting a requirement for new protein synthesis. In both myoblasts and myotubes protein degradation was accompanied by an increased expression of the α-type subunits of the 20S proteasome as well as functional activity of the proteasome, as determined by the ‘chymotrypsin-like’ enzyme activity. There was also an increased expression of the 19S regulatory complex as well as the ubiquitin-conjugating enzyme (E2(14k)), and in myotubes a decrease in myosin expression was seen with increasing concentrations of proteolysis-inducing factor. These results show that proteolysis-inducing factor co-ordinately upregulates both ubiquitin conjugation and proteasome activity in both myoblasts and myotubes and may play an important role in the muscle wasting seen in cancer cachexia. British Journal of Cancer (2002) 86, 1628–1633. DOI: 10.1038/sj/bjc/6600236 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-05-20 2002-05-03 /pmc/articles/PMC2746596/ /pubmed/12085214 http://dx.doi.org/10.1038/sj.bjc.6600236 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Experimental Therapeutics
Gomes-Marcondes, M C C
Smith, H J
Cooper, J C
Tisdale, M J
Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor
title Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor
title_full Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor
title_fullStr Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor
title_full_unstemmed Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor
title_short Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor
title_sort development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor
topic Experimental Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746596/
https://www.ncbi.nlm.nih.gov/pubmed/12085214
http://dx.doi.org/10.1038/sj.bjc.6600236
work_keys_str_mv AT gomesmarcondesmcc developmentofaninvitromodelsystemtoinvestigatethemechanismofmuscleproteincatabolisminducedbyproteolysisinducingfactor
AT smithhj developmentofaninvitromodelsystemtoinvestigatethemechanismofmuscleproteincatabolisminducedbyproteolysisinducingfactor
AT cooperjc developmentofaninvitromodelsystemtoinvestigatethemechanismofmuscleproteincatabolisminducedbyproteolysisinducingfactor
AT tisdalemj developmentofaninvitromodelsystemtoinvestigatethemechanismofmuscleproteincatabolisminducedbyproteolysisinducingfactor